Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
S&P Global
SPGI
|
+$216M |
| 2 |
Charter Communications
CHTR
|
+$192M |
| 3 |
SLB Ltd
SLB
|
+$79.3M |
| 4 |
IBM
IBM
|
+$70.2M |
| 5 |
Newell Brands
NWL
|
+$67.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AFFX
Affymetrix Inc
AFFX
|
+$7.53B |
| 2 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$447M |
| 3 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$229M |
| 4 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$208M |
| 5 |
SANDISK CORP
SNDK
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.87% |
| 2 | Technology | 14.38% |
| 3 | Financials | 13.98% |
| 4 | Industrials | 10.32% |
| 5 | Consumer Discretionary | 9.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1026
Murphy USA
MUSA
$10.1B
| $17.4M | 0.01% |
235,002
-9,390
| -4% | -$612K |
2013 Q3
11 quarters
|
|
1027
DELISTED
Tupperware Brands Corporation
TUP
| $17.4M | 0.01% |
309,307
+9,323
| +3% | +$532K |
2013 Q2
12 quarters
|
|
1028
Home BancShares
HOMB
$5.88B
| $17.4M | 0.01% |
878,988
+6,992
| +0.8% | +$147K |
2013 Q2
12 quarters
|
|
1029
Ligand Pharmaceuticals
LGND
$5.88B
| $17.4M | 0.01% |
233,798
+22,805
| +11% | +$1.69M |
2013 Q2
12 quarters
|
|
1030
First Citizens BancShares
FCNCA
$24.2B
| $17.4M | 0.01% |
67,093
+2,438
| +4% | +$613K |
2013 Q2
12 quarters
|
|
1031
RLI Corp
RLI
$5.54B
| $17.4M | 0.01% |
504,604
-10,188
| -2% | -$332K |
2013 Q2
12 quarters
|
|
1032
Rollins
ROL
$16.2B
| $17.4M | 0.01% |
1,333,823
+42,667
| +3% | +$523K |
2013 Q2
12 quarters
|
|
|
JCP
1033
DELISTED
J.C. Penney Company, Inc.
JCP
| $17.3M | 0.01% |
1,946,169
+28,249
| +1% | +$248K |
2013 Q2
12 quarters
|
|
1034
Accendra Health
ACH
$21.6M
| $17.3M | 0.01% |
462,051
+12,590
| +3% | +$473K |
2013 Q2
12 quarters
|
|
1035
Elme Communities
ELME
$157M
| $17.3M | 0.01% |
548,949
-4,422
| -0.8% | -$130K |
2013 Q2
12 quarters
|
|
1036
Commercial Metals
CMC
$7.48B
| $17.3M | 0.01% |
1,021,330
+104,024
| +11% | +$1.79M |
2013 Q2
12 quarters
|
|
|
QTS
1037
DELISTED
QTS REALTY TRUST, INC.
QTS
| $17.2M | 0.01% |
308,056
+69,418
| +29% | +$3.58M |
2013 Q4
10 quarters
|
|
1038
Myriad Genetics
MYGN
$399M
| $17.2M | 0.01% |
561,028
+33,436
| +6% | +$1.16M |
2013 Q2
12 quarters
|
|
|
CPHD
1039
DELISTED
Cepheid Inc
CPHD
| $17.2M | 0.01% |
558,021
+30,053
| +6% | +$909K |
2013 Q2
12 quarters
|
|
1040
Zebra Technologies
ZBRA
$17.8B
| $17.1M | 0.01% |
342,341
+15,185
| +5% | +$883K |
2013 Q2
12 quarters
|
|
1041
Huntsman Corp
HUN
$1.52B
| $17.1M | 0.01% |
1,270,317
+27,186
| +2% | +$399K |
2013 Q2
12 quarters
|
|
1042
Enovis
ENOV
$1.13B
| $17.1M | 0.01% |
374,444
+9,619
| +3% | +$470K |
2013 Q2
12 quarters
|
|
1043
DELISTED
CATALENT, INC.
CTLT
| $16.9M | 0.01% |
736,896
+85,597
| +13% | +$2.26M |
2014 Q3
7 quarters
|
|
|
N
1044
DELISTED
Netsuite Inc
N
| $16.9M | 0.01% |
232,705
+7,761
| +3% | +$595K |
2013 Q2
12 quarters
|
|
1045
LTC Properties
LTC
$2.35B
| $16.8M | 0.01% |
325,532
+10,906
| +3% | +$519K |
2013 Q2
12 quarters
|
|
|
ICPT
1046
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
| $16.8M | 0.01% |
117,877
+5,104
| +5% | +$744K |
2013 Q2
12 quarters
|
|
|
IPXL
1047
DELISTED
Impax Laboratories, Inc.
IPXL
| $16.8M | 0.01% |
582,823
+82,673
| +17% | +$2.69M |
2013 Q2
12 quarters
|
|
1048
LivaNova
LIVN
$4.28B
| $16.8M | 0.01% |
334,322
-38,053
| -10% | -$1.92M |
2015 Q4
2 quarters
|
|
|
MDCO
1049
DELISTED
Medicines Co
MDCO
| $16.8M | 0.01% |
499,284
+13,455
| +3% | +$474K |
2013 Q2
12 quarters
|
|
|
MNDT
1050
DELISTED
Mandiant, Inc. Common Stock
MNDT
| $16.8M | 0.01% |
1,018,996
+114,081
| +13% | +$1.84M |
2013 Q4
10 quarters
|
|
Similar funds
Geode Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Geode Capital Management held 4,187 positions worth $184B, down 2.4% from $188B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Geode Capital Management withdrew a net $8.49B in Q2 2016, closing 127 positions and reducing 984 holdings. Its most notable exit was Affymetrix Inc, an estimated $7.53B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 14% a quarter earlier, followed by Technology and Financials.
Against the trend, Geode Capital Management opened a new position in S&P Global worth $215M.
- Geode Capital Management's largest Q2 2016 buy was S&P Global: 2,009,728 shares worth $215M.
- Geode Capital Management added most to Charter Communications in Q2 2016, an estimated $192M increase.
- Geode Capital Management's biggest Q2 2016 reduction was GE Aerospace, cutting an estimated $72.2M.
- Geode Capital Management fully exited Affymetrix Inc in Q2 2016, selling an estimated $7.53B.
- Geode Capital Management's ten largest holdings make up 15% of its $184B portfolio in Q2 2016.
- Geode Capital Management opened 96 new positions and closed 127 in Q2 2016.
- Geode Capital Management's portfolio value fell 2.4% quarter-over-quarter to $184B.
Based on Geode Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.